Cerebrolysin
Also known as: CBL, FPF-1070, Cere
Neuropeptide preparation / Neurotrophic agent — mixture of low-molecular-weight peptides and amino acids derived from porcine brain
What it is
Cerebrolysin is a neuropeptide preparation used in many countries for stroke recovery and Alzheimer's disease, though it is not approved in the USA. It's made from purified brain tissue and is thought to mimic protective growth signals in the nervous system. Approved in Europe and Asia for neurological conditions; not FDA-approved.
The scientific side
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. Its mechanism of action is described as resembling the activity of endogenous neurotrophic factors. Key reported mechanisms include: induction of neurogenesis, neuroplasticity, neuroprotection, and neurotrophicity; modulation of endogenous neurotrophic factor expression including BDNF, GDNF, NGF, CNTF, VEGF, IGF-1, and TNF-α (PMID 37052231, 22229324; IGF-1: PMID 19531281); stabilization of the blood-brain barrier by reducing pro-inflammatory and pro-coagulation proteins (ICAM-1, HMGB1, TNF-α, phosphorylated NF-κB-p65) and increasing tight junction proteins (ZO-1, occludin, claudin) in vitro; and protection of the neurovascular unit. The preparation contains neurotrophic factors including BDNF, GDNF, NGF, and CNTF among active peptide fragments. Its biological effects are described as similar to endogenous neurotrophic effects and it can cross the blood-brain barrier.
Class: Neuropeptide preparation / Neurotrophic agent — mixture of low-molecular-weight peptides and amino acids derived from porcine brain
Legal & regulatory status
Not approved for use in the USA. Regulatory approval status in other jurisdictions not explicitly stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Acute ischemic stroke (AIS) — neuroprotection and functional recovery Mixed
- Cochrane review of 7 RCTs (1773 participants). Moderate-certainty evidence that Cerebrolysin probably results in little to no difference in all-cause death (RR 0.96, 95% CI 0.65–1.41) and in total SAEs (RR 1.16, 95% CI 0.81–1.66). Moderate-certainty evidence of a potential increase in non-fatal SAEs (RR 2.39, 95% CI 1. PMID 37818733 Ziganshina et al., Cochrane Database Syst Rev (2023)
- Meta-analysis of 9 RCTs (N=1879). Cerebrolysin superior to placebo on NIHSS at day 30/21 (MW 0.60, P<0.0001). Combined NNT for clinically relevant NIHSS changes: 7.7 (95% CI 5.2–15.0). Ordinal mRS at day 90 in moderate-to-severe patients: MW 0.61 (95% CI 0.52–0.69, P=0.0118, N=314). Safety comparable to placebo. PMID 29248999 Bornstein et al., Neurol Sci (2018)
- Prospective comparative effectiveness study, 16 countries, 1769 patients with moderate IS (NIHSS 8–15). Median Cerebrolysin dose 30 mL, median duration 10 days. Superior to standard therapy on primary endpoint (mRS at 90 days; MW 0.6157, P<0.0001) and all secondary endpoints including MoCA. No differences in safety mea PMID 40851188 Vosko et al., Int J Stroke (2025) — C-REGS2
- Rapid health technology assessment of 14 publications (8 meta-analyses, 6 pharmacoeconomic studies). Cerebrolysin showed advantages in total efficacy rate, neurological function, upper limb motor function, and ADL recovery. Adverse reactions were mild or comparable to control. Pharmacoeconomic studies indicated cost-ef PMID 38552072 Wan et al., Medicine (2024)
- Meta-analysis of 6 RCTs (1649 patients). No significant effect on functional recovery at Day 90 by mRS (RR 1.33, P=0.28), NIHSS (RR 1.03, P=0.77), or Barthel Index (RR 0.95, P=0.44). No increase in adverse events, SAEs, or mortality vs placebo. PMID 28458521 Wang et al., Drug Des Devel Ther (2017)
- Meta-analysis of 7 RCTs (1779 patients). Summary results did not demonstrate superiority of Cerebrolysin on mRS or Barthel Index. Neutral effects on safety outcomes including mortality and SAE. PMID 28656143 Zhang et al., Biomed Res Int (2017)
- Prospective, randomized, open-label multicenter pilot study. Cerebrolysin 30 mL/day for 14 days added to alteplase (0.9 mg/kg) in 126 patients vs 215 controls (alteplase alone). Significantly decreased symptomatic HT (OR 0.248, 95% CI 0.072–0.851, P=0.019). Significant decrease in NIHSS score on day 14 (P=0.045). No di PMID 36973684 Khasanova & Kalinin, BMC Neurol (2023) — CEREHETIS
- Prospective multicenter study, 398 AIS patients. Cerebrolysin (20 IV infusions of 10 mL) and Cerebrolysin plus nootropics both showed significant improvements (P<0.001) in mRS, NIHSS, and MoCA at day 90 vs comparator nootropics alone. No drug-related adverse events. PMID 34414874 Tran et al., CNS Neurol Disord Drug Targets (2022)
- Acute ischemic stroke adjunct to mechanical thrombectomy / endovascular thrombectomy Human observational
- Single-center, prospective, open-label study with blinded outcome assessment; 50 consecutive EVT patients treated with Cerebrolysin (30 mL IV within 8 h of onset, continued to day 21, then second cycle at 69–90 days) vs 50 propensity score-matched historical controls. mRS 0–2 at 90 days: 68% vs 44% (P=0.016, OR 2.7; NN PMID 40325343 Staszewski et al., Transl Stroke Res (2025)
- Propensity-score matched cohort extension to 12 months (same protocol as PMID 40325343). Cerebrolysin associated with higher odds of 12-month functional independence (aOR 6.10, 95% CI 1.64–22.66; P<0.01) and favorable mRS shift (common OR 3.57; P<0.01). 12-month mortality similar (18% both groups). Fewer survivors requ PMID 41739286 Staszewski et al., Transl Stroke Res (2026)
- Meta-analysis of 3 observational studies (294 patients). Cerebrolysin + MT vs MT alone: Good functional outcome (mRS 0–3) RR 1.56 (95% CI 1.25–1.93, P<0.0001). Reduced sICH (RR 0.12, 95% CI 0.03–0.48, P=0.03). Mortality 64% lower in Cerebrolysin group (RR 0.36, 95% CI 0.18–0.68, P=0.02). Very slight heterogeneity (I²=2 PMID 41880098 Afridi et al., Brain Behav (2026)
- Post-stroke motor function recovery and rehabilitation Mixed
- Meta-analysis of CARS-1 and CARS-2 (2 prospective, randomized, double-blind, placebo-controlled trials). Cerebrolysin 30 mL/day for 21 days started 24–72 h after stroke onset combined with standardized rehabilitation. ARAT score superiority at day 90 (MW 0.62, P<0.0001). Early NIHSS benefit at day 14/21 (MW 0.59, P<0.0 PMID 28747461 Guekht et al., Neurol Sci (2017) — CARS meta-analysis
- Prospective, randomized, double-blind, placebo-controlled multicenter study. Cerebrolysin 30 mL/day for 21 days. Primary endpoint ARAT at day 90: MW 0.71 (95% CI 0.63–0.79, P<0.0001). Global status (12 scales): MW 0.62 (95% CI 0.58–0.65, P<0.0001). Premature discontinuation <5%. Cerebrolysin safe and well tolerated. PMID 26564102 Muresanu et al., Stroke (2016) — CARS trial
- Systematic review with meta-analysis elements (10 studies). Cerebrolysin at 30 mL dosage significantly improved daily activity during early comprehensive rehabilitation post-stroke. Significant restoration of affected upper limb function during long-term rehabilitation. Improvement in speech and social activity with sp PMID 41782528 Shmonin et al., Zh Nevrol Psikhiatr (2026)
- Post-stroke aphasia recovery Human RCT
- Prospective, randomized, double-blind, placebo-controlled multicenter RCT (2 Romanian centers). 123 patients (intention-to-treat) with left MCA ischemic stroke and nonfluent aphasia enrolled 3–5 days post-stroke. Cerebrolysin or placebo combined with speech and language therapy in 10-day cycles over 3 intervals. Cerebr PMID 39957612 Homberg et al., Stroke (2025) — ESCAS trial
- Alzheimer's disease (mild to moderate) Mixed
- Meta-analysis of 6 RCTs of Cerebrolysin 30 mL/day in mild-to-moderate AD. Cognitive function (SMD –0.40, P=0.0031 at 4 weeks). Global clinical change: OR 3.32 (P=0.0212) at 4 weeks; OR 4.98 (P=0.0150) at 6 months. Global benefit (combined): MW 0.57 at 4 weeks and 6 months (both P<0.002). Safety comparable to placebo. PMID 25832905 Gauthier et al., Dement Geriatr Cogn Disord (2015)
- Review of 30 years of clinical use. Cerebrolysin safe and efficacious in AD; may enhance and prolong efficacy of cholinergic drugs in moderate-to-advanced AD. Clinical trials demonstrated beneficial treatment effects on cognitive, global, and functional domains. PMID 32808294 Gavrilova & Alvarez, Medicinal Res Rev (2021)
- Review of multicenter RCTs. Statistically significant and clinically relevant treatment effects on cognitive, global and functional domains in mild-to-moderately severe dementia. Doses of 10 and 30 mL most effective; higher doses up to 60 mL most effective for neuropsychiatric symptoms. Efficacy persisted for several m PMID 22514793 Allegri & Guekht, Drugs Today (2012)
- Prevention of MCI-to-dementia conversion (Alzheimer's disease risk populations) Human observational
- 3-year prospective comparative study, 100 aMCI patients. Annual course therapy: 20 IV infusions of Cerebrolysin 20 mL in 100 mL saline for 4 weeks, repeated annually for 3 years (n=50) vs no therapy (n=50). Lower progression of cognitive deficits and significantly lower conversion rate to dementia in the Cerebrolysin g PMID 39435777 Ponomareva et al., Zh Nevrol Psikhiatr (2024)
- Prospective comparative study, 88 first-degree relatives of AD patients with aMCI. 46 received 3 courses of Cerebrolysin (20 IV infusions of 20 mL in 100 mL isotonic saline per course) vs 42 untreated. No aMCI-to-dementia conversions in treated group over 2.5 years; annual conversion rate 9.5% in comparison group (prob PMID 37655416 Selezneva & Gavrilova, Zh Nevrol Psikhiatr (2023)
- Vascular dementia Human RCT
- Cochrane review of 6 RCTs (597 participants). Combined MMSE and ADAS-cog+ data: SMD 0.36 (95% CI 0.13–0.58; very low-quality evidence). Global function response rate: RR 2.69 (95% CI 1.82–3.98; very low-quality evidence). No difference in adverse event rates. Authors note high risk of bias in included studies and insuf PMID 31710397 Cui et al., Cochrane Database Syst Rev (2019)
- Cochrane review of 6 RCTs (597 participants). Beneficial effect on general cognitive function (MMSE WMD 1.10; 95% CI 0.37–1.82; ADAS-cog+ WMD –4.01; 95% CI –5.36 to –2.66). Improved global clinical function (RR 2.71, 95% CI 1.83–4.00). No significant difference in non-serious adverse events. Insufficient evidence for r PMID 23440834 Chen et al., Cochrane Database Syst Rev (2013)
- Traumatic brain injury (moderate to severe) Mixed
- Prospective meta-analysis of two phase IIIb/IV RCTs (185 patients, GCS 6–12). Cerebrolysin: 50 mL/day for 10 days then two cycles of 10 mL/day for 10 days, add-on to usual care. Multidimensional primary endpoint: small-to-medium effect in favor of Cerebrolysin at Day 30 (MW 0.60, P=0.0156) and Day 90 (MW 0.60, P=0.0146 PMID 33620612 Vester et al., Neurol Sci (2021) — CAPTAIN trial series
- Retrospective study, 44 TBI patients (11 Cerebrolysin, 33 control). Cerebrolysin group received 30 mL IV infusions. Significant improvement in executive, cognitive, and functional performance; moderate residual disability; significant reduction in need for care at 7 months. PMID 37900065 Soto et al., J Med Life (2023)
- Retrospective multicenter cohort, 87 severe TBI patients. Cerebrolysin 30 mL/day for 14 days then 10 mL/day for 14 days (n=42) vs standard protocol (n=45). Favorable outcome at Day 21: 87% vs 50% (P<0.00001). GOS ≥4: 39% vs 18% (P=0.043). Mean hospital stay 7 days shorter in Cerebrolysin group (P<0.00001). No significa PMID 35344761 Lucena & Briones, Clin Neurol Neurosurg (2022)
- Amyotrophic lateral sclerosis (ALS) as add-on to riluzole Human RCT
- Phase II randomized, double-blind, placebo-controlled trial. 20 patients with ALS, all receiving riluzole 50 mg PO twice daily; Cerebrolysin group (n=10) received 10 mL IV once daily, 5 days/week for Month 1, then 3 days/week for Months 2–3. ALS-FRS-R: 2.3-point improvement from baseline to Month 1 in Cerebrolysin grou PMID 38585517 Firstenfeld et al., J Med Life (2023)
- Neurodevelopmental outcomes in high-risk preterm infants Human RCT
- RCT in high-risk preterm infants (<32 weeks gestation) with abnormal neurological assessment at 2 months corrected age. Randomized at 6 months corrected age to early intervention program ± Cerebrolysin injection 0.1 mL/kg body weight weekly for 3 months. Failed gross motor development at 12 months: 33% (Cerebrolysin) v PMID 33935111 Samir et al., J Neonatal Perinat Med (2022)
- Neonatal hypoxic-ischemic encephalopathy (HIE) Animal studies only
- Review: Cerebrolysin has up to 6-month treatment window post-ischemic insult. Cerebrolysin injections of 0.1 mL/kg body weight twice per week found to provide gross motor and speech deficit improvement in reviewed studies. Biomarker establishment warranted to improve patient outcomes. PMID 34494216 Fiani et al., Acta Neurol Belg (2021)
- Post-stroke depression and anxiety Animal studies only
- Animal study (male BALB/c mice, post-ischemic depression model). Cerebrolysin 2.5 mL/kg for 2 weeks reversed behavioral (anxiety, depressive-like, social) and molecular changes (corticosterone, oxidative stress, BDNF, NF-κB, Iba-1) induced by the PID model. PMID 35500360 Farajdokht et al., J Stroke Cerebrovasc Dis (2022)
- Antidepressant augmentation (lithium augmentation) in depression Animal studies only
- Animal study (rat reserpine model of depression). Cerebrolysin alone or combined with lithium alleviated behavioral, oxidative stress, acetylcholinesterase, monoamine, and BDNF changes. Combined lithium + Cerebrolysin showed superior benefit, suggesting potential as adjuvant antidepressant. PMID 38394763 Abdelaty et al., J Psychiatr Res (2024)
- Endothelial blood-brain barrier protection (in vitro) In vitro only
- In vitro study using human cerebral endothelial cell permeability assay. Cerebrolysin significantly reduced tPA- and fibrin-impaired endothelial cell permeability, reduced pro-inflammatory and pro-coagulation proteins (ICAM-1, HMGB1, TNF-α, p-NF-κB-p65), and elevated tight junction proteins (ZO-1, occludin, claudin). E PMID 33661804 Teng et al., Neuroreport (2021)
- Post-herpes simplex encephalitis neuropsychiatric symptoms In vitro only
- Case report: 33-year-old female with post-HSE neuropsychiatric symptoms. After acute-phase acyclovir and dexamethasone, Cerebrolysin was administered in the post-acute phase with significant cognitive improvement. Authors note need for further studies. PMID 41178897 Lee et al., J Med Life (2025)
- Hair repigmentation (unexpected off-target observation) Human observational
- Case series of 5 patients (mean age 70.6 years) receiving Cerebrolysin for neurological diseases. Scalp hair repigmentation observed during treatment, associated with greater melanin and MART-1/Melan-A staining on scalp biopsies post-treatment. First report of this phenomenon. PMID 36411485 Villarreal-Reyna et al., Eur J Med Res (2022)
Protocol
No community dose for Cerebrolysin on record yet.
All studies (38)
- PMID 23440834 Human RCT
Vascular dementia - PMID 31710397 Human RCT
Vascular dementia - PMID 33935111 Human RCT
Neurodevelopmental outcomes in high-risk preterm infants - PMID 38585517 Human RCT
Amyotrophic lateral sclerosis (ALS) as add-on to riluzole - PMID 39957612 Human RCT
Post-stroke aphasia recovery - PMID 36411485 Human observational
Hair repigmentation (unexpected off-target observation) - PMID 37655416 Human observational
Prevention of MCI-to-dementia conversion (Alzheimer's disease risk populations) - PMID 39435777 Human observational
Prevention of MCI-to-dementia conversion (Alzheimer's disease risk populations) - PMID 40325343 Human observational
Acute ischemic stroke adjunct to mechanical thrombectomy / endovascular thrombectomy - PMID 41739286 Human observational
Acute ischemic stroke adjunct to mechanical thrombectomy / endovascular thrombectomy - PMID 41880098 Human observational
Acute ischemic stroke adjunct to mechanical thrombectomy / endovascular thrombectomy - PMID 22514793 Mixed
Alzheimer's disease (mild to moderate) - PMID 25832905 Mixed
Alzheimer's disease (mild to moderate) - PMID 26564102 Mixed
Post-stroke motor function recovery and rehabilitation - PMID 28458521 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 28656143 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 28747461 Mixed
Post-stroke motor function recovery and rehabilitation - PMID 29248999 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 32808294 Mixed
Alzheimer's disease (mild to moderate) - PMID 33620612 Mixed
Traumatic brain injury (moderate to severe) - PMID 34414874 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 35344761 Mixed
Traumatic brain injury (moderate to severe) - PMID 36973684 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 37818733 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 37900065 Mixed
Traumatic brain injury (moderate to severe) - PMID 38552072 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 40851188 Mixed
Acute ischemic stroke (AIS) — neuroprotection and functional recovery - PMID 41782528 Mixed
Post-stroke motor function recovery and rehabilitation - PMID 19531281
- PMID 22229324
- PMID 33661804 In vitro only
Endothelial blood-brain barrier protection (in vitro) - PMID 34494216 Animal studies only
Neonatal hypoxic-ischemic encephalopathy (HIE) - PMID 35500360 Animal studies only
Post-stroke depression and anxiety - PMID 37052231
- PMID 38394763 Animal studies only
Antidepressant augmentation (lithium augmentation) in depression - PMID 39832667
- PMID 41178897 In vitro only
Post-herpes simplex encephalitis neuropsychiatric symptoms - PMID 41349847